Medina, Miguel, and Jesús Avila. "Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimer's Disease." Current Pharmaceutical Design, vol. 16, no. 25, 2010, pp. 2790-8.
Medina M, Avila J. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Curr Pharm Des. 2010;16(25):2790-8.
Medina, M., & Avila, J. (2010). Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Current Pharmaceutical Design, 16(25), 2790-8.
Medina M, Avila J. Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimer's Disease. Curr Pharm Des. 2010;16(25):2790-8. PubMed PMID: 20698823.
TY - JOUR
T1 - Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
AU - Medina,Miguel,
AU - Avila,Jesús,
PY - 2010/07/09/received
PY - 2010/07/21/accepted
PY - 2010/8/12/entrez
PY - 2010/8/12/pubmed
PY - 2011/2/9/medline
SP - 2790
EP - 8
JF - Current pharmaceutical design
JO - Curr Pharm Des
VL - 16
IS - 25
N2 - Originally discovered because of its role in the regulation of glucose metabolism, Glycogen Synthase Kinase-3 (GSK-3) it is now recognised as a crucial player in a diverse series of cellular processes involved in Alzheimer's disease (AD) pathology. Besides having been identified as the major tau protein kinase, GSK-3 mediates Aβ neurotoxicity, plays an essential role in synaptic plasticity and memory, might be involved in Aβ formation, and it has an important role in inflammation and neuronal survival, all key features of AD neuropathology. Moreover, AD was one of the earliest disorders linked to GSK-3 dysfunction. Thus, the discovery of small molecule GSK-3 inhibitors has attracted significant attention to the protein both as therapeutic target for the therapeutic intervention in neurodegenerative diseases as well as a means to understand the molecular basis of these disorders.
SN - 1873-4286
UR - https://www.unboundmedicine.com/medline/citation/20698823/Glycogen_synthase_kinase_3__GSK_3__inhibitors_for_the_treatment_of_Alzheimer's_disease_
L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=1381-6128&volume=16&issue=25&spage=2790&aulast=Medina
DB - PRIME
DP - Unbound Medicine